Showing results (301-310 of 523) with videos related to
Sort By:
Pageof 53
The Lancet. Respiratory Medicine|March 27, 2026
Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaborationAnne-Marie C Dingemans, Isabelle Opitz, Alessandro Brunelli, et al.Lung Cancer (Amsterdam, Netherlands)|November 15, 2022
A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM populationDavid Heredia, Luis Mas, Andres F Cardona, et al.NPJ Precision Oncology|June 26, 2026
Redefining therapeutic horizons in thymic epithelial tumors: precision, combinations, and emerging biologyJennifer A Marks, Rohan Maniar, Kavitha J Ramchandran, et al.Molecular Cell|November 29, 2007
Nonapoptotic role for Apaf-1 in the DNA damage checkpointYael Zermati, Shahul Mouhamad, Lilli Stergiou, et al.Lung Cancer (Amsterdam, Netherlands)|December 26, 2021
Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trialMariona Riudavets, Marie Naigeon, Matthieu Texier, et al.Journal for Immunotherapy of Cancer|February 8, 2022
CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockersBoris Duchemann, Marie Naigeon, Edouard Auclin, et al.BMJ Open|December 26, 2022
Epidemiological Study to Assess the Prevalence of Lung Cancer in patients with smoking-associated atherosclerotic cardiovascular diseases: PREVALUNG study protocolDavid Boulate, Marine Fidelle, Caroline Caramella, et al.Clinical Lung Cancer|June 12, 2017
A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung CancerBonnie Glisson, Benjamin Besse, Manuel Cobo Dols, et al.Therapeutic Advances in Medical Oncology|February 17, 2022
Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLCFilippo G Dall'Olio, Claudia Parisi, Laura Marcolin, et al.Expert Review of Anticancer Therapy|July 11, 2022
Immunosenescence, inflammaging, and cancer immunotherapy efficacyJulieta E Rodriguez, Marie Naigeon, Vincent Goldschmidt, et al.Pageof 53